Paradigm Shift Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Paradigm Shift Therapeutics's estimated annual revenue is currently $775k per year.
- Paradigm Shift Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Paradigm Shift Therapeutics has 5 Employees.
- Paradigm Shift Therapeutics grew their employee count by 0% last year.
Paradigm Shift Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Paradigm Shift Therapeutics?
Paradigm Shift Therapeutics, LLC (PSTx) was founded with a mission to develop transformational and affordable cancer therapies using a lean proof of concept approach. PSTx was launched in January 2014 by Teresa Burgess, Ph.D. and Kate Farrell, Ph.D. with an ongoing collaboration with Dr. David Roberts at the NCI focused on developing novel CD47-targeting inhibitors-a target with the potential to radically change cancer treatment. Thomas Miller, Ph.D. joined PSTx as a full partner in September 2014. The goal of our team is to develop inhibitors of CD47 that can be translated into clinical practice for treatment of patients with cancer.
keywords:N/A
N/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 5 | -17% | N/A |
#2 | $0.5M | 5 | 0% | N/A |
#3 | $0.8M | 5 | -55% | N/A |
#4 | $0.8M | 5 | -81% | N/A |
#5 | $0.4M | 5 | 0% | N/A |